Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
32.8M
-
Shares change
-
-3.96M
-
Total reported value, excl. options
-
$334M
-
Value change
-
-$102M
-
Put/Call ratio
-
1.39
-
Number of buys
-
92
-
Number of sells
-
-90
-
Price
-
$10.19
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q1 2025
219 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.8M shares
of 40.6M outstanding shares and own 80.75% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (2.79M shares), JPMORGAN CHASE & CO (2.6M shares), VANGUARD GROUP INC (2.57M shares), Logos Global Management LP (2M shares), MORGAN STANLEY (1.7M shares), Nantahala Capital Management, LLC (1.51M shares), ADAR1 Capital Management, LLC (1.49M shares), STATE STREET CORP (1.3M shares), D. E. Shaw & Co., Inc. (1.26M shares), and FEDERATED HERMES, INC. (1.22M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.